Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul-Aug;6(4):859-70.
doi: 10.4161/mabs.28965. Epub 2014 Apr 25.

Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies

Antoine Deslandes  1
Affiliations
Review

Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies

Antoine Deslandes. MAbs. 2014 Jul-Aug.

Abstract

Although there are currently more than 30 antibody-drug conjugates (ADC) in clinical development for the treatment of blood cancers and solid tumors, comparison of their clinical pharmacokinetics (PK) is challenging because of the large number of, and differences between, the targets, ADC constructs, dosing regimens, and patient populations. In this review, we standardized the evaluation, using non-compartmental PK data reported at Cycle 1, i.e., following the first drug administration of what is usually a repeated-dose treatment, in monotherapy. We report ADC clinical PK properties, dosing regimen, determination of doses ranges and associated maximum tolerated doses. We also evaluated the effect of structural characteristics and target types (hematological vs. solid tumors) on PK. In addition, we discuss how integration of PK/pharmacodynamics approaches on top of classical dose escalation in first-in-human studies may improve dosing regimen determination for subsequent phases of clinical development.

Keywords: antibody-drug conjugates; dose selection; dosing regimen; maximum tolerated dose; oncology; pharmacokinetics; phase I.

PubMed Disclaimer

Figures

None
Figure 1. ADC dose ranges and maximum tolerated doses in first-in-humans studies. Gray symbol: MTD; open symbol: MTD not reached.
None
Figure 2. ADC dose escalation profiles in first-in-human studies.
None
Figure 3. Dose-exposure relationship for ADC administered every 3 wk.
None
Figure 4. Effect of dose on ADC clearance, by target antigen type (HT, hematological tumor; ST, solid tumors. (Boxes indicate maximum tolerated dose in mg/kg)
None
Figure 5. Unconjugated drug plasma exposure vs. ADC plasma exposure.
See this image and copyright information in PMC

References

    1. Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis. 2013;5:997–1006. doi: 10.4155/bio.13.38. - DOI - PubMed
    1. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov. 2013;12:329–32. doi: 10.1038/nrd4009. - DOI - PubMed
    1. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs. 2012;30:1121–31. doi: 10.1007/s10637-011-9670-0. - DOI - PubMed
    1. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood. 2013;121:4838–41. doi: 10.1182/blood-2013-03-490482. - DOI - PubMed
    1. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Girish S. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet. 2013;52:657–72. doi: 10.1007/s40262-013-0060-y. - DOI - PubMed

MeSH terms